No doubt, the turbocharging of IP is in the assay matrices of production and potency. It's what separates MSB from Jacko pumping out stem cells churned out of a yoghurt maker in Manila and injecting them into eyeballs and spines for $10k a pop.
For a cell with a complex profile of powerful cascaded MOAs that move beyond the reductio ad absurdum pretence of single action drugs, assay matrices ARE the science behind a marketable product - for trial success, and potency guarantee for national approvals.
Cell Therapy News/Articles, page-17667
-
- There are more pages in this discussion • 119 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
98.0¢ |
Change
0.010(1.03%) |
Mkt cap ! $1.118B | |||
| Open | High | Low | Value | Volume |
| 96.0¢ | 99.0¢ | 95.5¢ | $5.286M | 5.409M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 91218 | 98.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 99.0¢ | 63577 | 4 |
View Market Depth
| Last trade - 16.10pm 27/06/2024 (20 minute delay) ? |
| MSB (ASX) Chart |